Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

Gout Clinical Trial

Official title:

A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01336686
• Other study ID #: M102-21122
• Status: Completed
• Phase: Phase 2
• First received: April 14, 2011
• Last updated: March 30, 2015
• Start date: May 2011
• Est. completion date: November 2011

Study information

• Verified date: March 2015
• Source: CymaBay Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: November 2011
• Est. primary completion date: November 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Read and sign the informed consent after the elements of consent have been fully explained and all questions have been addressed, prior to any study procedures.

• Known gout patient (per criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout in Appendix 3)

• the sUA must be = 8.0 mg/dL and =12 mg/dL

• if on ULT, the patients must agree to temporarily discontinue their existing ULT and the sUA must be = 8.0 mg/dL and =12 mg/dL after wash-out at Week -1

• Male or female, 18-75 years of age at Screening Visit

• All female patients must be surgically sterile or post-menopausal (at least 45 years of age with no history of menses for at least 2 years; or any age with no history of menses for at least 6 months and serum FSH = 40 mIU/mL) or have a partner who has undergone vasectomy or must agree to use two medically accepted methods of contraception including a barrier method (see the list in Appendix 4) for the entire duration of the study unless reporting complete sexual abstinence.

• Female patients must not be pregnant or lactating

• Male patients with a female partner of child-bearing potential must agree to use condom or the partner must use a medically acceptable method of contraception for the entire duration of the study.

• Patients must have an estimated CrCl = 60 mL/min as calculated by the Cockcroft-Gault method

• Serum creatinine value must be = 1.1 mg/dL in females and = 1.3 mg/dL in males

• Patients must have liver function tests = 1.5X ULN for AST, ALT and T-bilirubin, = 2X ULN for ALP, = 3X ULN for GGT; and = 3X ULN for CK

• All other clinical laboratory parameters must be within normal limits or considered not clinically significant for participation in this study

• Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically significant for participation in this study

• Patients must have a systolic blood pressure = 160 mm Hg and a diastolic blood pressure = 90 mm Hg; known hypertensive patients controlled with medication other than thiazide diuretics (BP reading as above) may be included

Exclusion Criteria:

• Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder, or organ transplant).

• Known patient with xanthinuria

• History of documented or suspected kidney stones

• Over producers of uric acid as evidenced by 24-hour urinary uric acid > 800 mg (on normal unrestricted diet)

• Known infection with the human immunodeficiency virus (HIV) or history of viral hepatitis type B or C

• History of illicit drug or alcohol abuse within last 1 year

• History of significant pulmonary disease, upper GI bleeding, documented peptic ulcer disease (unless known H. pylori infection treated successfully without recurrence), or nephrotic syndrome within last 3 years

• All patients must not have had a stroke, TIA, acute myocardial infarction, congestive heart failure (NYHA Class II-IV), angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization), lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy within last 5 years

• Malignancy within the last 5 years (except resected basal cell carcinoma)

• Body mass index (BMI) > 42 kg/m2

• Current or expected requirement for anticoagulant therapy (except for = 325 mg/day aspirin and/or Plavix® 75 mg/day)

• Rheumatoid arthritis or other autoimmune disease requiring ongoing treatment

• Current or expected treatment with potent CYP3A4 inhibitors (See in Appendix 6), ranolazine, digoxin, cyclosporine, cyclophosphamide and other cytotoxic agents, sulphonylurea, thiazolidinedione, diuretic, atypical antipsychotic agents, and phenytoin

• Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs use to treat acute flares are permitted)

• Current or expected treatment with systemic corticosteroids (except topical, ophthalmic, intra-articular, or inhaled at a dose < 1600 µg/day) other than to treat acute flares

• Known hypersensitivity to colchicine

• Treatment with any other investigational therapy within the 30 days prior to the Screening Visit, or patients who received at least one dose of blinded study drug while enrolled in any previous MBX-102 trial

• Any other condition that compromises the ability of the patient to provide informed consent or to comply with the objectives and procedures of this protocol, as judged by the investigator and/or medical monitor

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Gout
• Hyperuricemia

Intervention

Drug:
• Arhalofenate
Arhalofenate 400 mg once daily for 4 weeks
• Arhalofenate
Arhalofenate 600 mg once daily for 4 weeks
• Placebo comparator
Matching placebo once daily for 4 weeks
• Colchicine
0.6 mg colchicine daily for flare prophylaxis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
CymaBay Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum uric acid		Baseline and end of treatment phase (4 wks)	No